Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis.
erdafitinib
fibroblast growth factor receptor (FGFR) inhibitor
metastatic urothelial carcinoma
real-world analysis
treatment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
01
2023
accepted:
03
05
2023
medline:
9
6
2023
pubmed:
9
6
2023
entrez:
9
6
2023
Statut:
epublish
Résumé
Erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on a phase 2 clinical trial, revealing a 40% response rate, and 13.8 months overall survival. These FGFR genomic alterations are uncommon. Thus, real-world data on erdafitinb use is scant. We herein describe erdafitinib treatment outcome in a real world patient cohort. We retrospectively reviewed the data of patients treated with erdafitinib from 9 Israeli medical centers. Twenty-five patients with metastatic urothelial carcinoma (median age 73, 64% male, 80% with visceral metastases) were treated with erdafitinib between January 2020 to October 2022. A clinical benefit (complete response 12%, partial response 32%, stable disease 12%) was seen in 56%. Median progression-free survival was 2.7 months, and median overall survival 6.73 months. Treatment related toxicity ≥ grade 3 occurred in 52%, and 32% discontinued therapy due to adverse events. Erdafitinib therapy is associated with a clinical benefit in the real world setting, and associated with similar toxicity as reported in prospective clinical trials.
Sections du résumé
Background
UNASSIGNED
Erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on a phase 2 clinical trial, revealing a 40% response rate, and 13.8 months overall survival. These FGFR genomic alterations are uncommon. Thus, real-world data on erdafitinb use is scant. We herein describe erdafitinib treatment outcome in a real world patient cohort.
Methods
UNASSIGNED
We retrospectively reviewed the data of patients treated with erdafitinib from 9 Israeli medical centers.
Results
UNASSIGNED
Twenty-five patients with metastatic urothelial carcinoma (median age 73, 64% male, 80% with visceral metastases) were treated with erdafitinib between January 2020 to October 2022. A clinical benefit (complete response 12%, partial response 32%, stable disease 12%) was seen in 56%. Median progression-free survival was 2.7 months, and median overall survival 6.73 months. Treatment related toxicity ≥ grade 3 occurred in 52%, and 32% discontinued therapy due to adverse events.
Conclusions
UNASSIGNED
Erdafitinib therapy is associated with a clinical benefit in the real world setting, and associated with similar toxicity as reported in prospective clinical trials.
Identifiants
pubmed: 37293597
doi: 10.3389/fonc.2023.1151701
pmc: PMC10244774
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1151701Informations de copyright
Copyright © 2023 Rouvinov, Levanon, Peer, Sarfaty, Sarid, Neiman, Grikshtas, Rosenbaum, Kushnir, Talmor, Friger, Zarbiv, Gez, Dresler, Shalata, Meirovitz, Shrem, Yakobson, Mermershtain and Keizman.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Cancer Ther. 2017 Jun;16(6):1010-1020
pubmed: 28341788
N Engl J Med. 2019 Jul 25;381(4):338-348
pubmed: 31340094
Lancet Oncol. 2022 Feb;23(2):248-258
pubmed: 35030333
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
J Clin Oncol. 2021 Aug 1;39(22):2474-2485
pubmed: 33929895
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Ther Adv Med Oncol. 2021 May 18;13:17588359211015499
pubmed: 34046088
Eur Urol. 2022 Jan;81(1):95-103
pubmed: 34742583
N Engl J Med. 2021 Mar 25;384(12):1125-1135
pubmed: 33577729
Expert Rev Anticancer Ther. 2019 Oct;19(10):835-846
pubmed: 31544541
Future Sci OA. 2018 Oct 04;4(10):FSO341
pubmed: 30457576